Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.61 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21582926 | 0.82 | HPGD (0.63) | LMNAKMT2AHSD17B10MEN1POLB | |
| SCHEMBL13485781 | 0.82 | ANPEP (0.66) | FFAR1HTTLMNAKMT2AALDH1A1 | |
| SCHEMBL8351644 | 0.81 | ALDH1A1 (0.59) | HTTLMNAALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL19350633 | 0.81 | USP2 (0.56) | HTTLMNAKMT2AALDH1A1HSD17B10 | |
| SCHEMBL11269396 | 0.81 | LMNA (0.57) | FFAR1HTTLMNAKMT2AALDH1A1 | |
| SCHEMBL4614310 | 0.81 | USP2 (0.45) | FFAR1SLC6A3KMT2APOLBRAB9A | |
| SCHEMBL15206242 | 0.81 | USP2 (0.49) | SLC6A3ALDH1A1POLBRAB9ANPC1 | |
| SCHEMBL10717383 | 0.80 | CYP1A2 (0.68) | FFAR1HTTLMNAKMT2AALDH1A1 | |
| SCHEMBL8008062 | 0.80 | FFAR1 (0.61) | FFAR1HTTLMNAKMT2AALDH1A1 | |
| SCHEMBL13527504 | 0.79 | RAB9A (0.57) | FFAR1HTTLMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8569267-B2 | Tetracyclic tetrahydrofuran derivatives containing cyclic amine side chain | JANSSEN PHARMACEUTICA, NV (BE) | 2013-10-29 | — | — | US | disclosed |
| US-7488752-B2 | nor-seco himbacine derivatives; thrombosis, anticoagulants, anticancer agents; antiinflammatory agents; anticholesterol agents; cardiovascular disorders; antiarrhythmia agents; antiischemic agents; strokes; antiarthritic agents | SCHERING CORPORATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | JANSSEN PHARMACEUTICA, NV (BE) | 2008-10-23 | — | — | US | disclosed |
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | JANSSEN PHARMACEUTICA, NV (BE) | 2008-10-23 | — | — | US | disclosed |
| US-4234488-A | FLUORESCENT DYES | BAYER AKTIENGESELLSCHAFT (DE) | 1980-11-18 | — | — | US | disclosed |
| US-4147865-A | Benz-(C,D)-indolyl compounds | BAYER AKTIENGESELLSCHAFT (DE) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262076-A1 | Novel Tetracyclic Tetrahydrofuran Derivatives Containing Cyclic Amine Side Chain | HTR2C, HTR2A, HTR5A | FFAR1 154/4885SLC6A3 21/4885HTT 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.